Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells

Experimental Oncology

Volumn 32, Issue 1, 2010, Pages 10-14

  Lukyanova, N Yu ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

A2780 cells; Cisplatin; Doxorubicin; Drug resistance; Homocysteine; Immunocytochemistry; MCF 7 cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HOMOCYSTEINE; PROTEIN BCL 2; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL VIABILITY; COLORIMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CADHERINS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HOMOCYSTEINE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77950590418     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chekhun VF, Kulik GI, Yurchenko OV, et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Letters 2006; 231: 87-93.
2. Chekhun VF, Lukyanova NYu, Yurchenko OV, et al. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp Oncol 2005; 27:191-195.
3. Chekhun VF, Shishova YuV. Current opinion on development of tumor drug resistance. Oncology 2000; 2:11-15 (In Russian).
4. Kurpeshev OK, Tsyb AF, Mardynsky YuS, et al. Mechanisms of development and overcoming of tumor resistance. Rus J Oncol 2002; 6:48-52 (In Russian).
5. Chekhun VF, Ganina KP, Kulik GI, et al. Impact of tumor drug resistance phenotype on the dynamics of cisplatin-induced changes in chromatin structure of peripherial blood limphocytes nuclei from rats with Guerin carcinoma. Cytology and Genetics 2000; 34: 17 (In Russian).
6. Li DJ, Zhang YZ, Zhang DH. Activity of telomerase and extracellular regulated protein kinases in parental and drag resistant cells of leukemia and ovarian cancer. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12: 304-308.
7. Yoon KA, Ku JL, Yang JO, et al. Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines. Int J Mol Med 2003; 11:343-348.
8. Arts HJG, Katsaros D, Vries EGE, et al. Drug resistance associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999; 5: 2798-2805.
9. Chekhun VF, Shishova YuV, Yurchenko OV, et al. Synergy between cisplatin and IPO-4 monoclonal antibodies against human epidermoid carcinoma K B cells. Exp Oncol 1998; 20: 210-216 (In Russian).
10. Miller AL, Kelly GS. Homocysteine metabolism: Nutritional modulation and impact on health and disease. Alt Med Rev 1997; 2: 234-254.
11. McCully KS. The biomedical significance of homocysteine. J Sci Expl 2001; 15: 5-20.
12. Shevchenko OP. Homocysteine - a new risk factor in atherosclerosis and thrombosis (lecture). Clinical Laboratory Diagnostics 2004; 10: 25-31 (In Russian).
13. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomo-cysteinemia as a risk factor for deep-vein thrombosis. NEJM 1996; 334:759-762. (Pubitemid 26089357)
14. Rassmusen B, Moller J. Total homocesteine measurement in clinical practice. Ann Clin Biochem 2000; 37:627-648.
15. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicol 1997; 123: 33-40.
16. PentyukOO, Il'chenko OV, Shevchuk SV, et al. Study of homocysteine concentrations in biological fluids using HPLC method. Works Podillya Academy Fundamental Applied Sci 2000; 2: 54-60 (In Ukrainian).
17. Brenner B. Thrombophilia and cancer in the pathogenesis of arterial thrombosis. J Clin Basic Cardiol 2000; 30: 89-90.
18. Zhu BT. Medical hypothesis: Hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. J Oncol 2003; 22: 499-508.
19. Gvozdev VA. Regulation of gene activity as a result of DNA chemical modification (methylation). Soros Educ J 1999; 10:11-17 (In Russian).
20. Robertson KD, Jones PA. DNA methylation: Past, present and future directions. Carcinogenesis 2000; 21:461-467.
21. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nature Rev Genetics 2000; 1: 11-19.
22. Zingg J-M, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997; 18: 869-882.
23. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38: 285-303.
24. Kuranaga N, Shinomiya N, Mochizuki H. Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: An in vitro study. BMC Cancer 2001; 1:10-18.
25. Enokida H, Shiina H, Igawa M, et al. CpG hyper-methylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004; 64: 5956-5962.
26. David GL, Yegnasubramanian S, Kumar A, et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: Changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther 2004; 3: 540-548.
27. Perkins C, Kim CN, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000; 95:1014-1022.
28. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1999; 94:1086-1099.
29. Oudard S, Levalois C, Andrieu JM, et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 2002; 22: 121-128.
30. Kim HH, Park CS. Lipotropes regulate bcl-2 gene expression in the human breast cancer cell line, MCF-7. In Vitro Cell Dev Biol Anim 2002; 38: 205-207.
31. Ding S, Gong BD. Methylation profile ofthe promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 3433-440.
32. Zhao CQ, Young MR, Diwan BA, et al. Association of arsenic-induced malignant transformation with DNA hypo-methylation and aberrant gene expression. Proc Natl Acad Sci USA 1997; 94: 10907-10912.
33. Dit Faute MA, Laurent L, Ploton D, et al. Distinctive alteration of invasiveness, drug resistance and cell-cell organization in 3D-cultires of MCF-7, a human breast cancer cell line, and its multidrug resistance variant. Clin Exp Metastasis 2002; 19:161-168.
34. Ni J, Hollander D. Application ofthe MTT-assay to functional studies of mouse intestinal intraepithelial lymphocytes. J Clin Lab Anal 1996; 10: 42-52.
35. Yurchenko O, Shlapatska L, Skryma M, et al. Immu-nohistochemical studies of CD150 expression in some human tumors. Exp Oncol 2003; 25: 186-190.
36. Lukyanova NYu, Rusetskaya NV, Tregubova NA, et al. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009; 31: 87-92.
37. Hajjar KA. Homocysteine: A sulph'rous fire. J Clin Invest 2001; 107: 663-664.
38. Jakubowski H. Homocysteine is a protein amino acid in humans. J Biol Chem 2002; 227: 30425-30428.